Guggenheim initiated coverage of ADC Therapeutics with a Buy rating and $11 price target. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on ADCT: JPMorgan biotech/pharma analysts hold an analyst/industry conference call ADC Therapeutics falls -13.5% ADC Therapeutics falls -20.2% ADC Therapeutics falls -15.3% ADC Therapeutics expects cash runway to extend into 4Q25